Outset Medical

Outset Medical is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System is an enterprise solution approved for use across the entire continuum of care — from hospital to home, allowing dialysis to be delivered anytime, anywhere, by anyone.

website: outsetmedical.com


NephU – Through increased awareness, collaboration, and information-sharing, our mission is to improve the future outcomes for individuals with kidney disease and other related conditions. NephU offers your organization private, in-person and virtual educational programs on a range of kidney health topics. future outcomes for individuals with kidney disease and other related conditions.

website: https://nephu.org/

Vifor Pharma

Vifor Pharma Group is a global pharmaceutical company. It aims to become the global leader in iron deficiency, nephrology, and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.

website: https://www.viforpharma.com/

Akebia Therapeutics

Founded in 2007, Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. As a leader in the renal community, we leverage scientific expertise and commercial capabilities to deliver unique therapeutics to address the complications of kidney disease.   We are located in the biotech hub of Kendall Square in Cambridge, Massachusetts, where we are inspired by our peers and dedicated to working with our partners, patients, advocacy organizations and the broader renal community. We have both a commercially available product, and a late-stage candidate for the potential treatment of anemia due to CKD.

website: https://www.akebia.com/


Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling comorbidities. The Company’s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

website: https://www.astrazeneca-congress-us.com/renal1/our-medicines


A leader in dialysis access and renal care solutions. Explore our educational resources and training videos on acute/chronic hemodialysis, including a 1-Credit CE course on Maximizing the Success of Catheter-Based Hemodialysis.

website: Medtronic.com